TITLE

NICE recommending cladribine for severe active RRMS

PUB. DATE
November 2017
SOURCE
PharmacoEconomics & Outcomes News;11/18/2017, Vol. 791 Issue 1, p37
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
126306572

 

Related Articles

  • Measures in the first year of therapy predict the response to interferon beta in MS.  // Current Medical Literature: Multiple Sclerosis;2009, Vol. 1 Issue 3, p68 

    The article reports on the result of the study which performs clinical and magnetic resonance imaging (MRI) evaluation of multiple sclerosis (MS) patients upon initiation of disease-modifying treatments (DMTs).

  • Nephrogenic Systemic Fibrosis. Klotter, Jule // Townsend Letter;Jul2011, Issue 336, p26 

    The article discusses the role of the paramagnetic metal gadolinium in causing nephrogenic systemic fibrosis (NSF) in people with severe kidney insufficiency. Gadolinium is used in chelate form in many magnetic resonance imaging (MRI) contrast agents to allow the scan to pick up more detail. The...

  • Neutralizing antibodies and interferon treatment of multiple sclerosis: addressing the open questions. Oger, J. // Multiple Sclerosis (13524585);May2007 Supplement 1, Vol. 13, pS5 

    The article discusses the significance of neutralizing antibodies (NAbs) and interferon on the treatment for multiple sclerosis (MS). The interferon beta therapies signified clear disease-modifying activity in MS that reduced relapse rate and magnetic resonance imaging disease burden. It is...

  • Measuring evoked responses in multiple sclerosis. Comi, G.; Leocani, L.; Medaglini, S.; Locatelli, T.; Martinelli, V.; Santuccio, G.; Rossi, P. // Multiple Sclerosis (13524585);Aug99, Vol. 5 Issue 4, p263 

    Evoked potentials (EPs) have been widely utilised in Multiple Sclerosis (MS) patients to demonstrate the involvement of sensory and motor pathways. Their diagnostic value is based on the ability to reveal clinically silent lesions and to objectivate the central nervous system damage in patients...

  • The Decade of the Brain. Rolak, Loren A. // Inside MS;Spring2001, Vol. 19 Issue 2, p44 

    Offers a look at the 1990s which was designated by the United States Congress as the decade of the brain in order to focus on the treatment of illnesses that affect the nervous system such as multiple sclerosis. Role of magnetic resonance imaging; Effect of white blood cells in myelin; Benefits...

  • Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Prosperini, Luca; Giann�, Costanza; Leonardi, Laura; De Giglio, Laura; Borriello, Giovanna; Galgani, Simonetta; Pozzilli, Carlo; Gasperini, Claudio // Multiple Sclerosis Journal;Jan2012, Vol. 18 Issue 1, p64 

    Objective: To evaluate whether an escalation approach was more effective in suppressing clinical and magnetic resonance imaging (MRI) activity than switching among immunomodulators in relapsing�remitting multiple sclerosis (RRMS) patients.Methods: In this post-marketing, prospective,...

  • Magnetization transfer imaging in multiple sclerosis treated with alemtuzumab. Button, Tom; Altmann, Dan; Tozer, Dan; Dalton, Catherine; Hunter, Kelvin; Compston, Alastair; Coles, Alasdair; Miller, David // Multiple Sclerosis Journal;Feb2013, Vol. 19 Issue 2, p241 

    The magnetization transfer ratio reflects the integrity of tissue structure, including myelination and axonal density. Mean magnetization transfer ratio fell in 18 untreated patients with multiple sclerosis both in normal appearing grey (–0.25 pu/year, p < 0.001) and white matter...

  • Determinants of Gd-enhanced MRI response to IFN-β-1a treatment in relapsing-remitting multiple sclerosis. Koudriavtseva, T.; Pozzilli, C.; Fiorelli, M.; Gasperini, C.; Bagnato, F.; Galgani, S.; Frontoni, M.; Ciccarelli, O.; Bastianello, S. // Multiple Sclerosis (13524585);Oct98, Vol. 4 Issue 5, p403 

    The decision to use interferon beta (IFN-β) as a treatment for relapsing-remitting multiple sclerosis (RRMS) is based on both clinical characteristics and course of the disease. To better identify the profile of responders, the relationships between baseline clinical/MRI characteristics and...

  • Antinuclear antibodies and response to IFNβ-1a therapy in relapsing-remitting multiple sclerosis. Ciccarelli, O.; Bagnato, F.; Mainero, C.; Salvetti, M.; Paolillo, A.; Gasperini, C.; Bastianello, S.; Pozzilli, C. // Multiple Sclerosis (13524585);Jun2000, Vol. 6 Issue 3, p137 

    We determined whether positive ANA was related to response to rIFNβ-1a in 62 relapsing-remitting MS patients. According to the presence of antinuclear antibodies (ANA) at baseline and during the first 6 months of treatment, patients were sorted in different groups. The clinical and MRI...

  • Gender-related differences in multiple sclerosis patients. TAO Chun-rong; ZHANG Ying-qian // Chinese Journal of Contemporary Neurology & Neurosurgery;Apr2013, Vol. 13 Issue 4, p349 

    Although multiple sclerosis (MS) affects both women and men, women are more susceptible to MS than men with increasing incidence and prevalence. Accumulating evidence indicates that gender appears to play a critical role in the development, efficacy and prognosis of MS, and therefore should be...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics